French biopharmaceutical Osivax, which is developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, has announced the successful first close of its Series B ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient response without serious adverse effects.

We are very pleased to have recently received European Commission approval for KOSTAIVE® and MHLW approval for Meiji Seika Pharma and ARCALIS to add commercial manufacturing sites in Japan.

Osivax secures strategic funding to accelerate the development of its influenza vaccine candidates: Lyon, France Wednesday, March 5, 2025, 16:00 Hrs [IST] Osivax, a biopharmaceuti ...

Detailed price information for Arcturus Therapeutics Ltd (ARCT-Q) from The Globe and Mail including charting and trades.

Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported ...

The company is pleased to welcome Meiji Seika Pharma Co., Ltd, a leading Japanese pharmaceutical company specializing in infectious diseases, as a new investor. With a legacy spanning over 75 ...

On the manufacturing front, Meiji Seika Pharma, our Japanese vaccine partner, submitted a manufacturing and marketing application in February for a new vial presentation of KOSTAIVE provided in a ...